Captrust Financial Advisors Has $70,000 Holdings in OmniAb, Inc. (NASDAQ:OABI)

Captrust Financial Advisors decreased its stake in shares of OmniAb, Inc. (NASDAQ:OABI) by 25.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 16,599 shares of the company’s stock after selling 5,801 shares during the period. Captrust Financial Advisors’ holdings in OmniAb were worth $70,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of OABI. Towerview LLC grew its position in shares of OmniAb by 114.0% during the 2nd quarter. Towerview LLC now owns 535,000 shares of the company’s stock worth $2,006,000 after buying an additional 285,000 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after purchasing an additional 194,835 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of OmniAb by 6.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Isthmus Partners LLC lifted its holdings in shares of OmniAb by 37.2% in the 2nd quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock worth $1,981,000 after purchasing an additional 143,387 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of OmniAb in the 2nd quarter worth $449,000. Institutional investors and hedge funds own 72.08% of the company’s stock.

OmniAb Stock Performance

Shares of NASDAQ:OABI opened at $3.79 on Tuesday. The stock’s fifty day simple moving average is $4.03 and its two-hundred day simple moving average is $4.19. OmniAb, Inc. has a 1-year low of $3.56 and a 1-year high of $6.72. The stock has a market cap of $535.21 million, a PE ratio of -6.11 and a beta of -0.14.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on OABI. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.